News for Healthier Living

ESMO 2026: Immunotherapy Combination Extends Survival in Advanced Endometrial Cancer

MADRID, OCTOBER 24, 2026 - An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

October 24, 2026


October 24 2026

October 23 2026

October 22 2026

October 21 2026

October 20 2026

October 19 2026

October 18 2026

October 17 2026

October 16 2026

October 15 2026

October 14 2026

October 13 2026

October 12 2026

October 11 2026

October 10 2026